Electra Therapeutics, Inc.

expected

Sep 17, 2026

per news reports

status

Filed with SEC

proposed ticker

ETRA

The expected listing date (Sep 17, 2026) comes from news reporting, not a regulatory filing — regulators publish a filing or approval date, not the day a company starts trading. See the source. It is replaced automatically if an official date is published.

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

United States

Incorporated in

Underwriters (from filing)

Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C

Overview

— AI-generated from the filing, see note below

Business overview

Electra Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing precision medicines aimed at treating immune-mediated diseases and cancer. The company targets signal regulatory proteins (SIRP) to selectively deplete disease-driving immune cells while preserving normal immune function. Its lead product candidate is ipsoprubart, a monoclonal antibody currently in clinical trials for secondary hemophagocytic lymphohistiocytosis (sHLH). Electra also has ELA822, a SIRPγ-specific monoclonal antibody in early-phase trials for T cell-mediated immune disorders.

Revenue model

Not disclosed in the provided filing text.

Last FY net loss

$62M

Competitive strengths

Innovative SIRP-targeted approach
Strong clinical trial results with ipsoprubart
Breakthrough Therapy designation from the FDA
Proprietary library of SIRP-targeted antibodies

Risk factors

Limited operating history and no approved products
Significant operating losses and no revenue generated so far
Risks associated with drug development, including regulatory approval and commercialization
Potential need for additional capital to continue operations and trials

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The expected date is Sep 17, 2026. The proposed ticker is ETRA. Underwriters on the deal include Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C. Electra Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Biological Products, (No Diagnostic Substances).

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Electra Therapeutics, Inc..

Biotech IPOs United States IPOs Jefferies LLC IPOs TD Securities (USA) LLC IPOs Evercore Group L.L.C IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/electra-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Electra Therapeutics, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/electra-therapeutics?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/electra-therapeutics/opengraph-image

Attribution text

Electra Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/electra-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=electra-therapeutics

Track this IPO

Get emailed when Electra Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

When is Electra Therapeutics, Inc. expected to go public?

Electra Therapeutics, Inc. is expected to list on Sep 17, 2026.

What is Electra Therapeutics, Inc.'s ticker symbol?

Electra Therapeutics, Inc.'s proposed ticker is ETRA.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Sep 14, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.